Introduction {#s1}
============

The neurological complications of human immunodeficiency virus 1 (HIV-1) infection, collectively known as HIV-associated neurocognitive disorders (HAND), remain an important and unmet clinical need ([@bib22]). While the introduction of combination antiretroviral therapy (ART) has significantly reduced the severity of neurological impairments in HIV+ individuals, approximately 30--50% of infected patients will develop some form of neurocognitive dysfunction ([@bib58]). Additionally, these impairments continue to be important determinants of quality of life, as well as disease progression ([@bib63]; [@bib69]).

The neuropathology of HAND is complex and has shifted dramatically since the implementation of ART ([@bib36]); however, the presence of chronic, low-level inflammation and viral neurotoxins disrupt neuroprotective and bioenergetic mechanisms that converge on aberrant synaptodendritic pruning and functional alterations in neurons ([@bib16]; [@bib47]; [@bib53]; [@bib57]; [@bib58]; [@bib66]). Developing novel adjuvant therapies that correct these dendritic alterations may be an effective strategy to help neurons face the multiple chronic insults associated with HIV infection and rescue cognitive function in these patients. A reduction in the number of dendritic spines, the main sites of excitatory neurotransmission, in the frontal cortex of HIV+ patients is significantly correlated with neurocognitive impairment ([@bib23]; [@bib34]). This finding has been recapitulated in animal models of HAND, including the non-infectious HIV-1 transgenic (HIV-Tg) rat ([@bib13]; [@bib48]). HIV-Tg rats are being increasingly used in HAND research, as they recapitulate key neurochemical, genetic, and behavioral features of the human pathology as seen in treated patients, such as undetectable viral replication, reduction of post-synaptic markers, neuroinflammation, changes in gene expression, and behavioral deficits ([@bib13]; [@bib25]; [@bib26]; [@bib37]; [@bib48]; [@bib49]; [@bib52]; [@bib70]; [@bib71]). In these animals, as in patients, viral proteins are expressed at low levels in the brain - including in the prefrontal cortex, an area involved in higher cognitive functions and neuroHIV ([@bib1]).

The chemokine CXCL12 and its main signaling receptor CXCR4 regulate several critical steps of CNS development, including neuronal survival and neuronal-glial communication ([@bib3]; [@bib18]; [@bib27]; [@bib42]). Our previous findings in differentiated central neurons suggested that the chemokine could also modulate spine morphology, an important factor for input-specific alterations in synaptic strength ([@bib73]), particularly in the mature brain. Dendritic protrusions are often grouped into four major classes: mushroom, thin, and stubby spines and filopodia ([@bib44]). Mushroom and thin spines are classically considered mature structures, while stubby spines and filopodia are thought of as immature or spine precursors, respectively ([@bib5]).

Here, we report that intracebroventricular (ICV) administration of CXCL12 completely rescues dendritic spine loss and cognitive dysfunction in the HIV-Tg rat. The chemokine specifically increased the number of thin spines, which are associated with learning and plasticity, in layer II/III pyramidal neurons of the medial prefrontal cortex (mPFC). In the same animals, upregulation of spine density by CXCL12 correlates with an improvement in cognitive flexibility, a task mediated by the mPFC. Our mechanistic studies demonstrate the essential role of the Rac1/PAK pathway in mediating the effects of CXCL12 on dendritic spines and cognition. Overall, this study provides evidence of complete restoration of structural and functional deficits in a model of HAND, reveals a novel fundamental role of CXCL12 in the mature brain, and identifies the molecular pathway responsible for CXCL12-mediated restoration of dendritic spines and cognitive performance.

Results {#s2}
=======

Attentional set-shifting is impaired in adult male HIV-Tg rats {#s2-1}
--------------------------------------------------------------

We have previously reported reductions in overall dendritic spine density in layer II/III pyramidal neurons in the mPFC in HIV-Tg rats ([@bib13]); however, it is currently unknown if these pathophysiological alterations result in discernable cognitive dysfunction. We assessed cognitive flexibility in adult male WT and HIV-Tg rats utilizing an automated three-phase lever pressing paradigm ([@bib6]). In the first two phases of the task (position discrimination and position reversal), there was a slight but significant difference between WT and Tg rats for position discrimination (30.17 ± 2.212 TTC for WT compared to 52.50 ± 11.90 TTC for Tg; [Figure 1A](#fig1){ref-type="fig"}) and none observed for position reversal (81.17 ± 18.11 TTC for WT compared to 64.50 ± 4.19 TTC for Tg; [Figure 1B](#fig1){ref-type="fig"}). In the shift to cue phase, however, Tg rats performed significantly worse than control animals ([Figure 1C](#fig1){ref-type="fig"}). Only four out of six Tg animals reached criterion by day 10 of the set-shifting phase and those who did complete the task took significantly longer to reach criterion (949.5 ± 146.3 TTC compared to 350.8 ± 84 TTC for WT). Additionally, a linear regression analysis on the cumulative proportion of animals reaching criterion over sessions revealed that a different curve was best fit for each group (F~(1,11)~=15.94, p=0.0021) further illustrating the gap between the groups in the number of sessions needed to reach criterion ([Figure 1D](#fig1){ref-type="fig"}).

![Male adult HIV-Tg rats are deficient in strategy shifting and initial rule discrimination, but not reversal learning.\
(**A**) HIV-Tg rats performed worse on the position discrimination task compared to age- and sex-matched WT animals. N = 6 animals/group, \*p\<0.05. (**B**) No significant differences were observed between WT and HIV-Tg rats on position reversal. N = 6 animals/group (**C**) Fewer HIV-Tg rats reached criterion on the shift to cue phase and took significantly greater number of trials to reach criterion. N = 6 animals/group, \*\*p\<0.01. (**D**) HIV-Tg rats took significantly longer to reach criterion as assessed via linear regression. N = 6 animals/group, (F~(1,11)~=15.94, p=0.0021).\
Figure 1---source data 1.HIV-Tg behavior raw data and statistical analysis.](elife-49717-fig1){#fig1}

While we have previously reported changes in dendritic spine numbers in the Tg rat ([@bib13]), it is unclear whether subtle alterations in spine morphology, which have implications for input-specific changes in synaptic strength, also occur. From the same set of animals used in the above-mentioned behavioral study, we assessed dendritic spine density and morphology in layer II/III pyramidal neurons in the prelimbic (PrL) region of the mPFC. Compared with control animals, Tg rats had significantly reduced dendritic spine density, as we previously observed in older animals ([@bib13]) ([Figure 2A](#fig2){ref-type="fig"}). In addition to spine density, subtle spine morphological changes were also present, whereby the density of thin ([Figure 2B](#fig2){ref-type="fig"}) and mushroom spines was reduced ([Figure 2C](#fig2){ref-type="fig"}), while stubby spines were upregulated ([Figure 2D](#fig2){ref-type="fig"}). This demonstrates a shift in spine morphology from mature (mushroom and thin) to immature (stubby), which is expected to alter cognition. Indeed, spine density in the mPFC was negatively correlated with performance to the shift to cue phase (Pearson's r = −0.7368, p=0.0151, α = 0.05; [Figure 2E](#fig2){ref-type="fig"}) and this relationship became stronger when only thin spine density was considered (Pearson's r = −0.7920, p=0.0063, α = 0.05; [Figure 2F](#fig2){ref-type="fig"}). On the contrary, spine density in the mPFC was not correlated with performance on position discrimination (Pearson's r = −0.4548, p=0.1374, α = 0.05) or position reversal (Pearson's r = 0.4862, p=0.1090, α = 0.05; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

![Layer II/III pyramidal neurons in the PrL region of the mPFC of HIV-Tg rats have alterations in spine density and morphology.\
(**A**) Dendritic spine density and morphology were assessed using Neurolucida 360 software. Male HIV-Tg rats had a reduction in overall dendritic spine density in layer II/III pyramidal neurons in the mPFC. N = 6 animals/group, 8 dendrites measured for each animal and averaged into single data point. \*\*\*p\<0.001. (**B**) On the same set of dendrites, thin spine density was significantly decreased in male HIV-Tg rats compared to sex-matched WT controls. N = 6 animals/group. \*\*\*p\<0.001. (**C**) As seen with overall and thin spine density, HIV-Tg rats had reduced mushroom spine density compared to WT controls. N = 6 animals/group. \*\*\*p\<0.001. (**D**) In contrast, stubby spine density was significantly elevated in male HIV-Tg rats. N = 6 animals/group. \*p\<0.05. (**E**) Across both groups, overall dendritic spine density in layer II/III pyramidal neurons in the mPFC were negatively associated with trials to criterion in the shift to cue phase. N = 12 animals; Pearson's r = −0.7368, p=0.0151. (**F**) When only thin spine density was considered, the relationship with shift to cue trials to criterion became even stronger. N = 12 animals; Pearson's r = −0.7920, p=0.0063.\
Figure 2---source data 1.HIV-Tg dendritic spines raw data and statistical analysis.](elife-49717-fig2){#fig2}

CXCL12 treatment enhances cognitive flexibility in HIV-Tg rats {#s2-2}
--------------------------------------------------------------

Based on the above findings and our previous work on neuronal CXCR4 signaling ([@bib42]; [@bib45]), we hypothesized that exogenous administration of CXCL12 could alleviate structural and cognitive deficits in Tg rodents. Tg rats were implanted with a unilateral cannula targeted to the lateral ventricle and allowed to recover for seven days prior to initiation of once-a-day infusions with vehicle (0.1% BSA in PBS, 5 μL total volume) or CXCL12 (5 ng/μL, 5 μL total volume) throughout the duration of the three-phase behavioral task ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

Both groups performed similarly across the first two phases (position discrimination and position reversal) of the behavioral task, with animals reaching criterion in approximately one day ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). In the shift to cue task, CXCL12-treated rats took significantly fewer trials to reach criterion than vehicle-treated counterparts (for animals who reached criterion: 701.3 ± 97.26 TTC for CXCL12 compared to 1191 ± 114.5 TTC for vehicle). Additionally, a greater number of rats given CXCL12 (n = 7 out of 10) completed the task compared to vehicle-treated animals (n = 2 out of 9; p=0.03; [Figure 3A](#fig3){ref-type="fig"}). A linear regression analysis on the cumulative proportion of animals reaching criterion over the ten sessions demonstrated that the CXCL12-treated rats completed the task at a significantly faster rate, F~(1,16)~=44.3781, p\<0.001 ([Figure 3B](#fig3){ref-type="fig"}), further emphasizing that CXCL12 rescues cognitive flexibility in this animal model, even after deficits are already present. Parallel studies in male WT rats ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) showed that vehicle- and CXCL12-treated WT rodents performed at a similar level across all three phases of the task, indicating that long term exposure to CXCL12 does not result in any deleterious effects on cognition as measured by the attentional set-shifting task.

![Once daily CXCL12 treatment significantly enhanced set-shifting abilities of HIV-Tg rats and completely restored dendritic spine density and morphology in the mPFC.\
(**A**) A greater percentage of CXCL12-treated rats reached criterion on the shift to cue phase and also took significantly fewer trials to complete the task. N = 9 animals/vehicle and 10 animals/CXCL12, p=0.03. (**B**) The rates at which the groups reached criterion were significantly different, with CXCL12-treated animals learning at a faster rate. N = 9 animals/vehicle and 10 animals/CXCL12, F~(1,16)~=44.3781, p\<0.001. (**C**) Representative image of DiOlistically labeled mPFC slices from HIV-Tg rats treated with either vehicle or CXCL12. (**D**) Adult male HIV-Tg rats treated with CXCL12 had significantly higher overall dendritic spine density in layer II/III pyramidal neurons of the mPFC. N = 9 animals/vehicle and 10 animals/CXCL12, 8 dendrites measured for each animal and averaged into single data point, \*\*\*p\<0.001 (**E**) Further analysis on spine morphology revealed a specific increase in the number of thin spines. N = 9 animals/vehicle and 10 animals/CXCL12; \*\*\*p\<0.001. (**F**) CXCL12 treatment resulted in a significant reduction in stubby spine density in HIV-Tg rats. N = 9 animals/vehicle and 10 animals/CXCL12; \*\*\*p\<0.001 (**G**) As previously observed, overall dendritic spine density was significantly negatively associated with trials to criterion on the set-shifting phase. N = 19 animals, Pearson's *r* = −0.7676, p=0.0157. (**H**) This relationship became even stronger when only thin spines were correlated with the number of trials required to complete the task. N = 19 animals, Pearson's *r* = −0.8493, p=0.0038.\
Figure 3---source data 1.WT and HIV-Tg ±CXCL12 raw data and statistical analysis.](elife-49717-fig3){#fig3}

In this same set of animals, we evaluated spine density and morphology in layer II/II pyramidal neurons of the mPFC. Once-a-day infusion with CXCL12 significantly upregulated overall dendritic spine density ([Figure 3C,D](#fig3){ref-type="fig"}), as well as the number of thin spines ([Figure 3E](#fig3){ref-type="fig"}), while also decreasing stubby spine density ([Figure 3F](#fig3){ref-type="fig"}). There were no observed changes in mushroom spines or filopodia. Strikingly, overall spine density in CXCL12-treated Tg rats was not significantly different from WT rats treated with vehicle, consistent with the complete recovery of behavior we observed in these rodents ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). We observed similar effects on spine density and morphology in WT rats ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}), despite no perceived alterations in behavior, most likely reflecting a ceiling effect. Overall spine density in the mPFC was negatively correlated with trials to criterion in the shift to cue phase (Pearson's *r* = −0.7676, p=0.0157, α = 0.05; [Figure 3G](#fig3){ref-type="fig"}), while thin spine density demonstrated an even stronger relationship with performance (Pearson's *r* = −0.8493, p=0.0038, α = 0.05; [Figure 3H](#fig3){ref-type="fig"}). Taken together, this is the first study to demonstrate complete recovery of both dendritic spine density and cognitive performance in the HIV-Tg rat, pointing to the potential therapeutic value of enhanced neuroprotective CXCR4 signaling.

CXCL12 activates Rac1 in a CXCR4- and Gαi-dependent manner in cortical neurons {#s2-3}
------------------------------------------------------------------------------

The mechanism by which CXCL12/CXCR4 signaling modulates dendritic spine density and morphology is presently unknown. There is substantial evidence in non-neuronal cells that CXCL12 can activate the small Rho GTPase, Ras-related C3 botulinum toxin substrate 1 (Rac1) that acts as a critical regulator of actin polymerization and stabilization. When Rac1 is in its active form, it is bound to GTP, which allows it to physically interact with the serine/threonine kinase PAK1. Thus, we utilized a Rac1 activity assay that uses PAK1 agarose beads to specifically pull down Rac1 bound to GTP. Cultured neurons (21 DIV) were treated with CXCL12 (20 nM) and lysates were subjected to pulldown to isolate Rac1-GTP. In line with previous reports in non-neuronal cells, CXCL12 significantly upregulates levels of Rac1-GTP at both 5 and 15 min with a return to basal levels by 30 min ([Figure 4A](#fig4){ref-type="fig"}). Furthermore, there were no alterations in the total levels of Rac1, demonstrating that CXCL12 is altering the amount bound to GTP.

![CXCL12 activates the small GTPase Rac1 in cultured cortical neurons in a CXCR4- and Gαi-dependent manner.\
(**A**) Cultured cortical neurons (21 DIV) were treated with CXCL12 (20 nM) for the indicated time points and subjected to pulldown using PAK agarose beads. Immunoblotting revealed a significant activation of Rac1 at 5 and 15 min and a return to baseline at 30 min. Positive and negative controls were performed by incubating lysates with GTPγS and GDP, respectively. N = 3 (**B**) Pretreatment with the CXCR4 antagonist, AMD3100 (100 ng/mL; 20 min) attenuated CXCL12-induced activation of Rac1. Positive and negative controls were performed by incubating lysates with GTPγS and GDP, respectively. N = 3 (**C**) Pretreatment with the Gαi inhibitor pertussis toxin (PTX, 100 ng/mL; 18 hr) completely prevented activation of Rac1 by CXCL12. Positive and negative controls were performed by incubating lysates with GTPγS and GDP, respectively. N = 3.](elife-49717-fig4){#fig4}

CXCR4 and its coupling to pertussis-toxin (PTX) sensitive Gαi proteins is essential for the ability of CXCL12 to upregulate dendritic spine density ([@bib45]). Pretreatment with either the specific CXCR4 inhibitor (AMD3100; 100 ng/mL, 20 min) or PTX (100 ng/mL, 18 hr) completely blocks the ability of CXCL12 to activate Rac1 in cortical neurons ([Figure 4B and C](#fig4){ref-type="fig"}). These results, as observed with dendritic spine density ([@bib45]), support the involvement of CXCR4 and its G-protein dependent signaling in CXCL12-induced Rac1 activation in cortical neurons.

CXCL12 phosphorylates downstream mediators of Rac1 and results in a shift in the F/G actin ratio {#s2-4}
------------------------------------------------------------------------------------------------

Activation of Rac1 facilitates dendritic spine stability and actin polymerization through phosphorylation of downstream proteins, including PAK1, LIMK1, and cofilin. In CXCL12-treated neurons, we observed a time-dependent increase in phosphorylation in PAK1 (Thr423), LIMK1 (Tyr507/508), and cofilin (Ser3) ([Figure 5A](#fig5){ref-type="fig"}). In line with our observations regarding Rac1 activation, inhibition of CXCR4 and Gαi signaling completely blocked CXCL12-induced phosphorylation of PAK1, LIMK1, and cofilin ([Figure 5B and C](#fig5){ref-type="fig"}). Thus, CXCL12-mediated activation of Rac1 results in the phosphorylation of proteins critical for dendritic spine stability through CXCR4 and PTX-sensitive Gαi proteins.

![CXCL12 phosphorylates downstream mediators of the Rac1 pathway and results in changes to actin polymerization in cortical neurons.\
(**A**) Cultured cortical neurons (21 DIV) were exposed to CXCL12 (20 nM) for the indicated time points and the phosphorylation status of PAK1, LIMK1, and cofilin was examined. CXCL12 treatment resulted in a time-dependent increase in the phosphorylation of all three proteins. N = 3, \*p\<0.05, \*\*p\<0.01. (**B**) Pretreatment with AMD3100 (100 ng/mL; 20 min) blocked CXCL12-induced phosphorylation of Rac1 downstream mediators. N = 3, \*\*p\<0.01, \*\*\*p\<0.001. (**C**) Inhibition of Gαi signaling (via PTX) blocked the ability of CXCL12 to phosphorylate Rac1 downstream mediators. N = 3, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. (**D**) Following treatment with CXCL12, the protein phosphatase SSH1 is phosphorylated (and inactivated) in a time-dependent manner. N = 3, \*p\<0.05. (**E**) Separation of F and G-actin in cortical neurons revealed a shift in favor of F-actin following CXCL12 treatment. Latrunculin A (5 μM, 2 hr), a potent actin polymerization inhibitor, and jaspakinolide (5 μM, 2 hr), an inducer of actin polymerization, were used as internal controls for the assay. N = 3; \*p\<0.05.\
Figure 5---source data 1.Densitometry statistical analysis.](elife-49717-fig5){#fig5}

The protein phosphatase Slingshot homolog 1 (SSH1) is known to regulate the phosphorylation status of both LIMK1 and cofilin ([@bib65]). Dephosphorylated/active SSH1 exhibits dual activity in that it dephosphorylates and activates cofilin and, in parallel, dephosphorylates and inactivates LIMK1, resulting in the release of the brake imposed by LIMK1 on cofilin ([@bib43]). However, phosphorylation of SSH1 at Ser978 causes inactivation such that SSH1 can no longer dephosphorylate and inactivate LIMK1/activate cofilin ([@bib39]). CXCL12 increased phosphorylation of SSH1 after one hour, demonstrating that not only does CXCL12 regulate the phosphorylation status of LIMK1 and cofilin through activation of Rac1 and PAK1, but also through inactivation of SSH1 ([Figure 5D](#fig5){ref-type="fig"}).

Increases in phosphorylated cofilin (Ser3) by either LIMK1 activation or SSH1 inactivation culminate in F-actin polymerization and a reduction in actin filament turnover. Therefore, we would expect a shift in the F/G-actin ratio in favor of F-actin in response to activation of this pathway by CXCL12. Cortical neurons treated with CXCL12 for one or two hours exhibited a four-fold increase in the F/G-actin ratio relative to vehicle-treated controls, indicative of a shift towards increased actin polymerization ([Figure 5E](#fig5){ref-type="fig"}). This functional change in the actin ratio is consistent with the time-dependent increase in dendritic spines induced by CXCL12 ([@bib45]). These findings suggest that CXCL12-induced activation of the Rac1/PAK pathway in cortical neurons through CXCR4-, Gαi-dependent mechanisms, results in measurable, functional changes in actin polymerization, consistent with those needed for dendritic spine stability.

CXCL12 specifically increases thin spine density via activation of Rac1 {#s2-5}
-----------------------------------------------------------------------

We observed activation of Rac1 and its downstream mediators by CXCL12 in cortical neurons, resulting in functional alterations in the F/G-actin ratio. Since these changes are associated with dendritic spine stability, we sought to investigate whether CXCL12 could upregulate a specific spine type. Thin spines appear to be likely targets for this signaling cascade due to the rapid F-actin polymerization and depolymerization that leads to their quick formation and elimination, often over the course of minutes. Rat primary cortical neurons (21 DIV) were exposed to CXCL12 (20 nM) for three hours; this treatment has previously been shown to elicit a peak effect of CXCL12 in cortical neurons ([@bib45]). Consistent with our signaling data, CXCL12 specifically increased thin spine density on these neurons ([Figure 6A](#fig6){ref-type="fig"}). On the same segment of dendrite analyzed for thin spine density, we observed a subsequent reduction in stubby spine density. This suggests, together with our data regarding the shift in the F/G-actin ration, that spine stabilization is increased following CXCL12 treatment.

![CXCL12 specifically modulates thin spine density via activation of Rac1.\
(**A**) Cultured cortical neurons (21 DIV) were treated with CXCL12 (20 nM, 3 hr), resulting in a specific increase in thin spine density and a decrease in stubby spine numbers. N = 9 coverslips/group, 4 dendrites measured/coverslip and averaged into single data point, 3 separate experiments, \*p\<0.05, \*\*\*p\<0.001. (**B**) Pretreatment with the specific Rac1 inhibitor NSC23766 (100 μM, 15 min) completely blocked CXCL12-induced activation of Rac1 in cortical neurons. N = 3 (**C**) Subsequently, inhibition of Rac1 activation by NSC23766 prevented phosphorylation of downstream mediators by CXCL12. N = 3, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. (**D**) Inhibition of Rac1 activation by NSC23766 blocked the ability of CXCL12 to modulate overall dendritic spine density, as well as thin and stubby spine density. N = 9 coverslips/group, 4 dendrites measured/coverslip and averaged into single data point, 3 separate experiments, \*p\<0.05, \*\*\*p\<0.001. (**E**) Cortical neurons (18 DIV) were infected with control or Rac1-shRNA viral particles and GFP-positive neurons were analyzed (21 DIV) following treatment with either vehicle or CXCL12. Knockdown of Rac1 inhibited CXCL12-mediated alterations in spine density and morphology. N = 9 coverslips/group, 4 dendrites measured/coverslip and averaged into single data point, 3 separate experiments, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.\
Figure 6---source data 1.In vitro raw data and statistical analysis.](elife-49717-fig6){#fig6}

To determine whether CXCL12 depends on the activation of Rac1 to modulate dendritic spine density and morphology we used both pharmacologic and molecular approaches. First, we determined that pretreatment of neuronal cultures with the specific Rac1 inhibitor NSC23766 ([@bib15]) (100 µg/mL; 15 mins) completely blocked CXCL12-induced activation of Rac1 ([Figure 6B](#fig6){ref-type="fig"}) and phosphorylation of its downstream mediators ([Figure 6C](#fig6){ref-type="fig"}). Next, we assessed alterations in dendritic spines by CXCL12 following either NSC23766 pretreatment or knockdown of Rac1 via shRNA (neurons infected at DIV 18 and treated on DIV 21). As shown in [Figure 6D](#fig6){ref-type="fig"}, the ability of CXCL12 to affect overall spine density and thin spine density was inhibited by blockade of Rac1 activation; furthermore, NSC23766 did not exhibit any effects on spine density or morphology on its own, demonstrating that acute inhibition of Rac1 does not negatively affect dendritic spines. Similarly, CXCL12 was unable to modulate spine density or morphology in Rac1 shRNA neurons ([Figure 6E](#fig6){ref-type="fig"}); in line with other studies ([@bib67]), prolonged inhibition of Rac1 expression by shRNA reduced total spine density (in either vehicle- and CXCL12-treated neurons). Taken together, these results point to the essential role of Rac1 activation in CXCL12-mediated dendritic spine alterations and provide the first mechanistic insight into this novel function of CXCL12.

In vivo inhibition of Rac1 stimulation prevents CXCL12-induced alterations of dendritic spines and cognitive flexibility {#s2-6}
------------------------------------------------------------------------------------------------------------------------

Our in vitro studies elucidated the critical role of Rac1 activation in regulating CXCL12-mediated dendritic spine changes. We also demonstrated that CXCL12 reverts dendritic spines and cognitive flexibility deficits in vivo. Hence, activation of Rac1 and its downstream mediators are likely implicated in these restorative effects. The next set of studies aims to test this hypothesis. Immunohistochemical analysis of pPAK1 in NeuN+ cells in layer II/III of the mPFC was conducted and multispectral imaging was used to quantify changes in phosphorylation levels in individual neurons (\~150--200 neurons per animal). While basal level of pPAK in HIV-Tg neurons was lower than WT, CXCL12 treatment in either genotype resulted in a robust increase in pPAK1 levels compared to vehicle-treated counterparts ([Figure 7A](#fig7){ref-type="fig"}). In Tg animals, the effect of CXCL12 on PAK1 activation was as evident as that seen in WT animals, resulting in a return to baseline phosphorylation levels. Since activation of PAK1 is intimately associated with alterations in dendritic spines and cognitive performance, we investigated the relationship between the two. This analysis showed that levels of pPAK1 in cortical neurons were positively correlated with overall dendritic spine density across all groups ([Figure 7B](#fig7){ref-type="fig"}), while it was negatively associated with trials to criterion on the shift to cue phase ([Figure 7C](#fig7){ref-type="fig"}). As predicted by the robust stimulation of pPAK1 in HIV-Tg animals, we observed no significant changes in total levels of Rac1 protein from frontal cortex lysates of WT and Tg animals ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Importantly, in line with our observation that Tg animals have lower pPAK1 stimulation at baseline, pulldown studies from PFC tissue of untreated rats demonstrated reduced levels of active Rac1 in Tg rats compared to WT animals ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}).

![CXCL12 administration increases phosphorylation of PAK1 in layer II/III pyramidal neurons in the mPFC of male WT and HIV-Tg rats.\
(**A**) Sections from the contralateral hemisphere used for dendritic spine analysis were subjected to immunohistochemical and multispectral analysis. Both adult male WT and HIV-Tg rats treated with CXCL12 had a significant increase in pPAK1 levels in NeuN+ cells in the mPFC. N = 4/group, \*p\<0.05 for WT+Veh vs WT+CXCL12, \*p\<0.05 for WT+CXCL12 vs Tg+CXCL12, and \*p\<0.05 for Tg+Veh vs Tg+CXCL12. (**B**) Phosphorylation of PAK1 in the mPFC was positively associated with overall dendritic spine density in the same set of animals. N = 14 animals, Pearson's r = 0.5602, p=0.0372. (**C**) Levels of phosphorylated PAK1 are negatively correlated with the number of trials to criterion on the set shift phase. N = 14 animals, Pearson's r = −0.5526, p=0.048.\
Figure 7---source data 1.Tyramide IHC raw data and statistical analysis.](elife-49717-fig7){#fig7}

We further investigated the role of Rac1 activation in regulating CXCL12-mediated dendritic spine dynamics and cognition in vivo. Prior to behavioral studies, the efficiency of in vivo Rac1 inhibition was assessed. Four-month old male rats were implanted with a unilateral cannula as previously described and following a seven-day recovery period, once daily infusions of either vehicle (diH~2~O) or NSC23766 (1 μg/μL or 2 μg/μL; 5 μL total volume) were initiated for eight days. At the end of the eight-day period, animals were sacrificed and one hemisphere was processed for Rac1 pulldown, while the other was utilized for immunohistochemical analysis of pPAK1. Immunoblotting revealed that both doses of NSC23766 significantly attenuated activation of Rac1 in frontal cortex lysates in a dose-dependent manner ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Additionally, there was a dose-dependent decrease in pPAK1 in NeuN+ cells in the contralateral hemisphere ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Thus, prolonged treatment with NSC23766 via ICV administration was well tolerated, and successfully downregulated activation of Rac1 and subsequent phosphorylation of its downstream mediators.

Based on the information generated from our initial experiments with NSC23766, we initiated studies to determine whether alterations in dendritic spines and cognitive flexibility induced by CXCL12 required Rac1 activation. Experiments were conducted in a similar manner as previous in vivo studies, though infusions of either vehicle or NSC23766 (2 μg/μL; 5 μL total volume) began one day prior to treatment with vehicle or CXCL12 (5 ng/μL; 5 μL total volume; [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). Inhibition of Rac1 was sufficient to prevent the improvement in cognitive flexibility by CXCL12 as measured by the number of animals reaching criterion (Veh+CXCL12 vs. NSC+CXCL12, p=0.0498) and rate to reach criterion (F~(3,32)~=12.6622, p\<0.001) ([Figure 8A and B](#fig8){ref-type="fig"}), while no changes were observed in the first two phases of the task ([Figure 8---figure supplement 3](#fig8s3){ref-type="fig"}). In the same set of animals used for behavioral analysis, cotreatment with NSC23766 blocked upregulation of overall dendritic spine and thin spine density ([Figure 8C and D](#fig8){ref-type="fig"}) and prevented decreases in the number of stubby spines ([Figure 8E](#fig8){ref-type="fig"}). As previously observed, overall dendritic spine density in the mPFC across all four groups was inversely correlated to cognitive performance in set-shifting (Pearson's *r* = −0.7862, p=0.0121, α = 0.05; [Figure 8F](#fig8){ref-type="fig"}); this correlation became stronger when only thin spine density was considered (Pearson's *r* = −0.8350, p=0.0058, α = 0.05; [Figure 8G](#fig8){ref-type="fig"}).

![Blockade of Rac1 activation prevents alterations in cognitive flexibility and dendritic spines by CXCL12.\
(**A**) Treatment with NSC23766 mitigated the ability of CXCL12 to increase the number of animals reaching criterion on the shift to cue phase. N = 12 animals/group, p=0.0498. (**B**) The rate at which animals reached criterion was significantly delayed with NSC23766 pretreatment as assessed via linear regression. N = 12 animals/group, F~(3,32)=~12.6622, p\<0.001. (**C**) Blockade of Rac1 activation by NSC23766 prevents CXCL12-mediated upregulation of overall dendritic spine density in the mPFC. N = 12 animals/group, 8 dendrites measured for each animal and averaged into single data point, \*\*p\<0.01. (**D**) Additionally, NSC23766 prevented changes in thin spine density induced by CXCL12. N = 12 animals/group, 8 dendrites measured for each animal and averaged into single data point, \*\*\*p\<0.001. (**E**) The ability of CXCL12 to decrease stubby spine density was blocked by NSC23766. N = 12 animals/group, 8 dendrites measured for each animal and averaged into single data point, \*\*p\<0.01. (**F**) As previously observed, overall dendritic spine density was negatively associated with trials to criterion on the set-shifting phase of the behavioral task. N = 23 animals, Pearson's *r* = −0.7862, p=0.0127. (**G**) This relationship became even stronger when only thin spine density was considered. N = 23 animals, Pearson's *r* = −0.8350, p=0.0051.\
Figure 8---source data 1.WT ±CXCL12/NSC23766 raw data and statistical analysis.](elife-49717-fig8){#fig8}

Based on the findings in WT rats, we extended our studies on Rac1 inhibition to HIV-Tg rats in order to determine the role of Rac1 activation on the ability of CXCL12 to positively modulate cognitive flexibility and dendritic spines in a neuroinflammatory environment. Co-treatment with NSC23766 completely abrogated the ability of CXCL12 to enhance attentional set-shifting in HIV-Tg rats, with fewer animals reaching criterion (55% for Veh+CXCL12 compared to 25% for NSC+CXCL12, [Figure 9A](#fig9){ref-type="fig"}) and taking significantly longer to reach criterion (F~(3,32)~=7.503, p=0.006, [Figure 9B](#fig9){ref-type="fig"}). As previously observed, inhibition of Rac1 activation had no deleterious effects on position discrimination and position reversal ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). Additionally, NSC23766 blocked the ability of CXCL12 to recover overall dendritic spine density ([Figure 9C](#fig9){ref-type="fig"}) and thin spine density ([Figure 9D](#fig9){ref-type="fig"}) in HIV-Tg rats, as well as decrease stubby spine density ([Figure 9E](#fig9){ref-type="fig"}). Despite no observed significant correlation between overall dendritic spine density and TTC in the shift to cue phase (Pearson's *r* = −0.2256, p=0.4808, α=0.05 [Figure 9F](#fig9){ref-type="fig"}), there was a strong negative correlation for thin dendritic spine density and shift to cue TTC (Pearson's *r* = −0.7787, p=0.0029, α = 0.05; [Figure 9G](#fig9){ref-type="fig"}). All together, these data demonstrate that CXCL12 depends on the activation of Rac1 to drive improvements in cognitive flexibility and dendritic spine number in physiological and neuroinflammatory conditions.

![CXCL12 depends on Rac1 activation to rescue cognitive flexibility and dendritic spine density in the HIV-Tg rat.\
(**A**) Inhibition of Rac1 activity blocked the ability of CXCL12 to positively enhance cognitive flexibility in an attentional set-shifting task. N = 9 for veh+veh, N = 9 for veh+CXCL12, N = 8 for NSC+veh, and N = 8 for NSC+CXCL12. (**B**) NSC23766 co-treatment significantly attenuated the rate at which animals reached criterion on the shift to cue phase as assessed by linear regression. N = 9 for veh+veh, N = 9 for veh+CXCL12, N = 8 for NSC+veh, and N = 8 for NSC+CXCL12, F~(3,32)~=7.503, p=0.0006. (**C**) Blockade of Rac1 activation abrogated the effect of CXCL12 on overall dendritic spine density in HIV-Tg rats. N = 9 for veh+veh, N = 9 for veh+CXCL12, N = 8 for NSC+veh, and N = 8 for NSC+CXCL12, eight dendrites measured for each animal and averaged into single data point, \*\*p\<0.01, \*\*\*p\<0.001. (**D**) CXCL12's impact on thin spines was mitigated by co-treatment with NSC23766. N = 9 for veh+veh, N = 9 for veh+CXCL12, N = 8 for NSC+veh, and N = 8 for NSC+CXCL12, eight dendrites measured for each animal and averaged into single data point, \*\*p\<0.01, \*\*\*p\<0.001. (**E**) NSC23766 prevented decreases in stubby spine density mediated by CXCL12 treatment. N = 9 for veh+veh, N = 9 for veh+CXCL12, N = 8 for NSC+veh, and N = 8 for NSC+CXCL12, eight dendrites measured for each animal and averaged into single data point, \*p\<0.05. (**F**) There was no significant relationship observed between overall dendritic spine density and trials to criterion on the set-shifting phase of the behavioral task. N = 12 animals, Pearson's *r* = −0.2256, p=0.4808. (**G**) Thin spine density was negatively associated with the number of trials to criterion in the shift to cue phase of the behavioral task. N = 12 animals, Pearson's *r* = −0.7787, p=0.0029.\
Figure 9---source data 1.HIV-Tg ±CXCL12/NSC23766 raw data and statistical analysis.](elife-49717-fig9){#fig9}

Discussion {#s3}
==========

The present study takes the critical steps in defining the molecular pathways mediating CXCL12 regulation of dendritic spines in the mature brain. These novel CXCL12-induced neuronal changes are instrumental for rescuing cognitive flexibility. Importantly, this work demonstrates recovery of executive function and dendritic spines when impairment is already present, opening up new therapeutic avenues for HAND and other neuroinflammatory conditions.

Complete rescue of behavioral and structural deficits in HAND {#s3-1}
-------------------------------------------------------------

Characterization of executive function deficits in HIV-Tg rats revealed selective alterations in set-shifting, but not initial rule discrimination or reversal learning. Thus, neuronal injury induced by viral neurotoxins or low-level inflammation that results in appreciable cognitive dysfunction may be restricted to particular brain regions. The mPFC, in particular the PrL region, is known to mediate strategy shifting, as inactivation or lesions to this area specifically impairs this behavioral phenotype while sparing both initial learning and reversal learning ([@bib4]; [@bib14]). On the other hand, damage to the anterior cingulate cortex or orbitofrontal cortex results in deficits in initial rule acquisition or reversal learning respectively ([@bib19]). Based on our behavioral data, we predict minimal changes in dendritic spines in these regions and ongoing studies in the same animal model are exploring whether other brain regions besides the mPFC display deficits in spine number and morphology. Regional analysis revealed selective alterations in the motor cortex, while there are marginal changes in the neighboring somatosensory cortex ([@bib41]). In line with clinical imaging studies ([@bib56]; [@bib55]), dendritic damage in the context of HIV infection seems to be region specific and very subtle. Importantly, our data are in line with others who have demonstrated subtle structural deficits of dopaminergic medium spiny neurons in the nucleus accumbens of female HIV-Tg rats ([@bib51]).

Using DiOlistic staining coupled with Neurolucida 360 software, we were able to successfully classify individual spines into one of the four main categories based on established parameters ([@bib50]). This revealed a significant increase in stubby spine density, associated with decreases in both thin and mushroom spine density, on layer II/III pyramidal neurons in the mPFC in HIV-Tg rats. This demonstrates an overall shift in spine morphology, whereby there is a greater proportion of immature (e.g. stubby) spines remaining on these neurons and fewer mature (e.g. thin and mushroom) ones. Combined with the overall reduction in spine density, this finding has major implications for neurotransmission and cognitive function. Stubby spines are considered immature structures due to their usual prevalence during early postnatal development and scarcity in the adult CNS ([@bib21]). Their lack of a distinctive head and neck suggests that these spines are unable to properly sequester incoming electrical and chemical signals, leading to inappropriate propagation of downstream pathways. Particularly, a dendritic spine's head and neck configuration is essential to properly compartmentalize incoming Ca^2+^ influx through glutamate receptors in order to prevent excitotoxicity from occuring ([@bib11]). Excitotoxic neuronal injury is a common endpoint for viral proteins and inflammatory mediators ([@bib58]) and the higher proportion of stubby dendritic spines may represent a common modality by which these proteins can induce damage. Additionally, electrophysiological data from HIV-Tg rats demonstrated that layer V pyramidal neurons from the PrL region of the mPFC are hyper-excitable compared to neurons from non-Tg controls, as indicated by reduced rheobase, spike amplitude, an inwardly-rectifying K^+^ influx, increased number of action potentials, and a trend towards aberrant firing ([@bib28]; [@bib71]). While our studies focused on dendritic spine alterations in layer II/III neurons, additional data from the same set of animals demonstrated similar deficits in layer V cells and recovery by CXCL12 administration (data not shown) suggesting that injury in the mPFC is not layer-specific. Thus, the increase in stubby spine density on these neurons may result in aberrant synaptic transmission and hyper-excitability, leading to inappropriate activation of Ca^2+^-dependent enzymes and structural damage to the neuron. This would result in considerable circuit alterations and behavioral dysfunction.

Notably, treatment with exogenous CXCL12 completely restored the reduction in dendritic spine density observed in the mPFC of HIV-Tg rats, as well as the associated dysfunction in set-shifting. To our knowledge, this is the first study reporting recovery of both structural and behavioral deficits in the HIV-Tg rat model. Importantly, studies were conducted at an age where animals were already impaired, demonstrating that dendritic spine injury and cognitive dysfunction are completely reversible. This has important implications for HIV+ patients on ART where viral replication has been suppressed, but viral proteins and inflammatory mediators may still be produced, especially in the CNS, and continue to induce damage ([@bib58]). It also supports the notion that targeting homeostatic mediators of neuronal function and synaptic transmission that are disrupted during HIV infection may be a valid therapeutic strategy for HAND patients. Our data also suggest that restoring highly plastic thin spines is a key driver in regulating cognitive function mediated by the mPFC. This is the first time this phenomenon has been reported in a rodent model of HAND, suggesting that therapeutics to target this spine type are an appropriate strategy to combat the deficits seen in these patients. Interestingly, the extended treatment with CXCL12 did not reveal any side effects in both WT and Tg animals, indicating that potential effects of the chemokine on other cellular targets ([@bib17]) do not interfere with its neuroprotective function - at least within the time frame of this study. Most importantly, our work dissecting out the molecular mechanisms of CXCL12-mediated spine alterations points to the key involvement of the Rac1/PAK pathway. Therefore, therapies targeting this pathway specifically in neurons would be beneficial in HAND and other types of cognitive dysfunction, such as aging ([@bib20]).

Role of Rac1/PAK pathway in CXCL12-enhanced cognitive performance {#s3-2}
-----------------------------------------------------------------

Though the chemokine CXCL12 is well known for its homeostatic action in the developing brain ([@bib33]), its relevance in the mature brain has been mainly associated with inflammatory responses. Here, we demonstrated that CXCL12 activates the small GTPase Rac1 and its downstream mediators to modulate dendritic spine density in mature, excitatory cortical neurons. Activation of this pathway is associated with actin polymerization and this resulted in a specific increase in thin spine density on cortical neurons. The involvement of the Rac1/PAK pathway in mediating the effects of CXCL12 on actin polymerization has not been described in cortical neurons. Our data show that Rac1 activation is the exclusive mediator of CXCL12's alterations on spine density and morphology, suggesting that targeted therapeutics to selectively activate this pathway through CXCR4 could recover dendritic spine loss. CXCL12 not only activated the Rac1/PAK pathway but also modulated the phosphorylation status of the phosphatase Slingshot homolog 1. This dual regulation of cofilin demonstrates that CXCL12 acts on multiple components of this pathway to exert control on actin polymerization. This also provides additional targets to positively modify dendritic spines. While it is presently unclear whether CXCL12 regulates phosphorylation of SSH1 in cortical neurons in a direct manner, there is evidence in non-neuronal cells that the chemokine can inhibit dephosphorylation of SSH1 via the 14-3-3 protein family ([@bib8]; [@bib9]). 14-3-3 proteins are a family of highly conserved proteins that are abundantly expressed in the adult brain ([@bib12]). They inhibit SSH1 phosphatase activity by binding to phosphorylated serine residues and sequestering SSH1 in the cytoplasm ([@bib40]; [@bib64]). Since our current data regarding CXCL12-induced activation of the Rac1/PAK pathway are in line with studies in non-neuronal cells, the mechanisms leading to SSH1 phosphorylation might also be conserved. However, this needs to be investigated.

Inactivation of Rac1 via a small molecule inhibitor completely blocked the beneficial effects of CXCL12 on set shifting as measured by trials to criterion and the rate to reach criterion. Furthermore, changes in spine density and morphology induced by daily CXCL12 treatment were completely dependent on its ability to activate Rac1 in the mPFC. Interestingly, blockade of Rac1 activation had no perceived effects on the first two phases of the behavioral task, suggesting specificity of the small GTPase in functions mediated by the mPFC but this warrants further investigation. Nevertheless, to our knowledge, this is the first study to connect Rac1 activation with behavioral flexibility, further underscoring the critical role of the small GTPase in regulating synaptic function. Additionally, our data support the notion that utilizing therapeutics to modulate Rac1/PAK signaling may be beneficial in reversing structural and behavioral deficits in the mPFC.

CXCL12 in the mature CNS {#s3-3}
------------------------

The role of CXCL12/CXCR4 in the developing CNS is well established. On the other hand, the effects of CXCL12 on mature neurons, specifically in the context of synaptic connectivity, are not completely understood. In cortical neurons, induction of Rac1 is associated with F-actin polymerization and spine stability ([@bib30]). This is in agreement with our data demonstrating a shift in F/G-actin ratio following CXCL12 treatment, as well as the specific increase in transient thin spines. Upregulation of thin spines, which at least initially only contain NMDARs and are considered 'silent synapses', would not be expected to result in significant alterations in synaptic transmission. However, as previously discussed, thin spines control neuronal signaling via regulation of calcium-dependent processes. Moreover, our previous work demonstrated that CXCL12 altered both sEPSC and mEPSC amplitude in whole-cell patch clamp slice recordings ([@bib45]). Changes in mEPSCs amplitude typically reflect alterations to postsynaptic receptors, suggesting that CXCL12 is contributing to the maturation of dendritic spines. Furthermore, Rac1 activation is implicated in spine head morphing, or twitching, that promotes the maturation of synaptic contacts ([@bib24]; [@bib67]). While we did not observe any changes in mushroom spine density by CXCL12 in vitro or in vivo, this is not surprising given that mushroom spines are the most mature and stable spines, typically implicated in long-term memory and potentiation ([@bib5]). Ongoing studies in the laboratory are investigating whether CXCL12 alters levels of post-synaptic density protein 95 (PSD-95), a necessary scaffolding protein present in mature synapses. Shifts in the actin ratio towards F-actin results in an increase in spine motility and spine head enlargement; thus, this chemokine plays a critical and unique role in regulating synaptic connectivity via modulation of the number of contacts as well as their maturation.

It is important to note that the relationship between CXCL12 and CXCR4 is not exclusive, as CXCL12 can also interact with another receptor, atypical chemokine receptor 3 (ACKR3), also known as CXCR7. ACKR3 contains a mutated 'DRYLAIV' motif ([@bib62]; [@bib68]), a region critical for G-protein coupling, and thus does not demonstrate G-protein-dependent signaling. Early reports supported a scavenger role, acting to internalize and degrade CXCL12, thereby regulating extracellular concentration. Removal of ACKR3 causes a significant increase in extracellular levels of CXCL12, which favors its binding to CXCR4 and triggers CXCR4 endocytosis and degradation ([@bib54]). Furthermore, ACKR3 can form heterodimers with CXCR4 and regulate CXCR4-mediated signaling; however, the presence of these heterodimers occurring in vivo has been called into question ([@bib29]; [@bib32]). While the above-mentioned evidence demonstrates that ACKR3 may modulate CXCR4 signaling pathways and responsiveness, the demonstrated absence of cell-surface ACKR3 in mature neurons (ACKR3 is only transiently expressed on the surface of developing neurons) ([@bib61]), suggests a predominant role of CXCR4 in CXCL12-mediated effects on dendritic spines and cognition.

While CXCR4 expression has been detected on other cell types of the CNS, including astrocytes ([@bib2]), microglia ([@bib31]), and oligodendrocytes ([@bib35]), CXCL12's effects on neurons are observed both in the presence and absence of glia ([@bib45]; [@bib60]), and its ability to regulate dendritic spines in cultured neurons is replicated in the intact brain. Thus, the chemokine's interaction with neuronal CXCR4 is sufficient to induce these changes. Our current studies aim to establish whether CXCL12 is modulating specific neuronal subpopulations (i.e. excitatory or inhibitory neurons). CXCL12 is known to alter GABAergic neurotransmission ([@bib3]; [@bib18]), which may result in dendritic spines changes on excitatory neurons ([@bib10]). Likewise, recent evidence has also shown that CXCL12 targets parvalbumin (PV)+ basket interneuron axons and inhibitory perisomatic synapses, which modulates neuronal excitability ([@bib72]). Ongoing experiments are utilizing dCas9-base CRISPR interference (CRISPRi) to selectively knockdown CXCR4 in either excitatory (CamKIIα+) or inhibitory (mDIx+) neurons and determine the contribution of each neuronal subpopulation to dendritic spine dynamics.

In conclusion, these studies open the possibility of creating therapeutics to target synaptic and cognitive deficits in HAND patients via restoration of endogenous neuroprotective pathways. While drug discovery involving chemokine receptors has primarily focused on developing antagonists, our work suggests that CXCR4 agonists may be beneficial in alleviating structural and behavioral dysfunction. The in vitro studies reported here dissected out the molecular players regulating CXCL12-induced spine changes, as well as identified the specific spine type targeted by the chemokine. The in vivo experiments validated our mechanistic studies and confirmed the involvement of Rac1 signaling in CXCL12-regulated dendritic spine and cognitive changes. Taken together, these data suggest that targeting these signaling pathways may represent a valid strategy for neurorestorative therapies for HAND and other diseases characterized by spine loss and/or CXCR4 dysregulation, such as Alzheimer's disease (AD) and schizophrenia. This represents a major paradigm shift, as previous attempts against HAND or AD focused on inhibition of excitotoxicity through targeting of glutamate receptors, transporters, or ion channels. Interestingly, small molecule CXCR4 agonists that may be exploited for further preclinical studies are now available ([@bib38]).

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                 Designation                                   Source or\                          Identifiers                                                          Additional\
  (species) or\                                                                               reference                                                                                                information
  resource                                                                                                                                                                                             
  --------------------------------------------- --------------------------------------------- ----------------------------------- -------------------------------------------------------------------- -------------------
  Strain, strain background (*R. Norvegicus)*   F344/NHsd (Male)                              Envigo and University of Maryland   RRID:[RGD_61109](https://scicrunch.org/resolver/RGD_61109)           

  Strain, strain background (*R. Norvegicus)*   HSD:HIV-1 (F344) (Male)                       Envigo and University of Maryland                                                                        

  Cell line (*H. sapiens*)                      HEK293T                                       ATCC                                RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)           

  Transfected construct (*R. Norvegicus*)       Rac1 shRNA                                    Origene Technologies                Cat \# TL712781                                                      

  Recombinant DNA reagent                       pCMVR8.74                                     AddGene                             RRID:[Addgene_22036](https://scicrunch.org/resolver/Addgene_22036)   

  Recombinant DNA reagent                       pMD2.G                                        AddGene                             RRID:[Addgene_12259](https://scicrunch.org/resolver/Addgene_12259)   

  Antibody                                      Anti-pPAK1 rabbit polyclonal (Thr423)         Cell Signaling Technology           RRID:[AB_330220](https://scicrunch.org/resolver/AB_330220)           1:1000

  Antibody                                      Anti-PAK1 rabbit polyclonal                   Cell Signaling Technology           RRID:[AB_330222](https://scicrunch.org/resolver/AB_330222)           1:1000

  Antibody                                      Anti-pLIMK1 rabbit polyclonal (Thr507/508)    EMD Millipore                       RRID:[AB_568901](https://scicrunch.org/resolver/AB_568901)           1:1000

  Antibody                                      Anti-LIMK1 rabbit polyclonal                  Cell Signaling Technology           RRID:[AB_2281332](https://scicrunch.org/resolver/AB_2281332)         1:1000

  Antibody                                      Anti-pCofilin rabbit polyclonal (Ser3)        Cell Signaling Technology           RRID:[AB_330238](https://scicrunch.org/resolver/AB_330238)           1:1000

  Antibody                                      Anti-Cofilin rabbit monoclonal                Cell Signaling Technology           RRID:[AB_10622000](https://scicrunch.org/resolver/AB_10622000)       1:1000

  Antibody                                      Anti-pSSH1L rabbit polyclonal (Ser978)        ECM Biosciences                     RRID:[AB_10553849](https://scicrunch.org/resolver/AB_10553849)       1:500

  Antibody                                      Anti-SSH1 rabbit monoclonal                   Cell Signaling Technology           RRID:[AB_2798263](https://scicrunch.org/resolver/AB_2798263)         1:1000

  Antibody                                      Anti-Rac1                                     Cell Biolabs                        Included in \#STA-401--1                                             1:6000

  Antibody                                      Anti-β-actin rabbit polyclonal                Sigma-Aldrich                       RRID:[AB_476693](https://scicrunch.org/resolver/AB_476693)           1:6000

  Antibody                                      Anti-MAP2\                                    EMD Millipore                       RRID:[AB_91939](https://scicrunch.org/resolver/AB_91939)             1:1000
                                                rabbit polyclonal                                                                                                                                      

  Antibody                                      Anti-pPAK1 rabbit polyclonal (Thr423)         Invitrogen                          RRID:[AB_2554427](https://scicrunch.org/resolver/AB_2554427)         1:25

  Antibody                                      Anti-NeuN rabbit monoclonal                   Cell Signaling Technology           RRID:[AB_2651140](https://scicrunch.org/resolver/AB_2651140)         1:400

  Antibody                                      Goat polyclonal anti-rabbit Alexa Fluor 568   Invitrogen                          RRID:[AB_143157](https://scicrunch.org/resolver/AB_143157)           1:250

  Peptide, recombinant protein                  Rat CXCL12                                    Peprotech                           Cat\# 400-32A                                                        

  Commercial assay or kit                       Rac1 Activity Assay Kit                       Cell Biolabs                        Cat\# STA-401--1                                                     

  Chemical compound, drug                       NSC23766                                      Tocris                              Cat\# 2161                                                           

  Software, algorithm                           GraphPad Prism                                GraphPad Software                   RRID:[SCR_015382](https://scicrunch.org/resolver/SCR_015382)         Version 8.0

  Software, algorithm                           Neurolucida 360                               MBF Biosciences                     RRID:[SCR_016788](https://scicrunch.org/resolver/SCR_016788)         Version 2017.01.4

  Software, algorithm                           Nuance Multispectral Imaging Systems          Nuance                              RRID:[SCR_015382](https://scicrunch.org/resolver/SCR_015382)         Version 2.10

  Software, algorithm                           Med-PC                                        Med Associates                      RRID:[SCR_012156](https://scicrunch.org/resolver/SCR_012156)         Version 4.1

  Other                                         Helios Gene Gun                               Bio-Rad                             Cat\# 1652411                                                        

  Other                                         Phalloidin Alexa Fluor 488                    Invitrogen                          Cat \# A12379                                                        1:400

  Other                                         Alexa Fluor conjugated tyramide 488           Invitrogen                          Cat \# B40953                                                        

  Other                                         Alexa Fluor conjugated tyramide 555           Invitrogen                          Cat\# B40955                                                         

  Other                                         DiI Stain                                     Invitrogen                          Cat\# D282                                                           

  Other                                         Hoechst                                       Invitrogen                          H3570                                                                1 μg/mL
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

Adult male wild-type (WT; F344/NHsd; n = 79) and HIV-1 transgenic rats (Tg; HSD:HIV-1(F344); n = 59, approximately 4 months old) were utilized for behavioral and dendritic spine analysis. Animals were purchased from Envigo Laboratories (Indianapolis, IN) until the license for breeding HIV-Tg rats was returned to the University of Maryland, who originally developed this transgenic line ([@bib48]). Rats were singly housed in isolation in our Association for Assessment and Accreditation of Laboratory Animal Care-accredited barrier facilities in accordance with the National Institutes of Health guidelines and institutional approval by the Institutional Animal Care and Use Committee. Animals were food-restricted one week prior to the initiation of lever pressing training.

Cannula implantation and intracerebroventricular administration {#s4-2}
---------------------------------------------------------------

Rats were implanted stereotaxically under isoflurane anesthesia and ketamine/xylazine (50 mg/kg; 10 mg/kg, PennVet), with 26-gauge stainless-steel guide cannulas (Plastics One) placed 0.96 mm posterior and 2.00 mm lateral to bregma, 3.5 mm below the surface of the cranium. Four stainless-steel screws (\#0--80) were placed around the cannula and acrylic dental cement was used to anchor them. Following surgery, animals were allowed seven days to recover before the initiation of infusions and behavioral testing. Animals received once daily infusions of either vehicle (0.1% BSA in PBS, 5 μL total volume), CXCL12 (5 ng/μL in 0.1% BSA in PBS, 5 μL total volume), or NSC23766 (2 μg/μL in diH~2~O, 5 μL total volume) via a micropump set for an infusion rate of 0.5 μL/min throughout the duration of behavioral testing.

Attentional set-shifting task {#s4-3}
-----------------------------

Reversal learning and strategy shifting were assessed using an automated operant-based approach whereby the behavioral tasks occurred within operant chambers controlled by custom software programs ([@bib6]). Each chamber was equipped with a house light, fan, two retractable levers, a tone generator above each lever, a pellet dispenser, a stainless-steel pellet trough located between the levers, and a panel light just above the pellet trough. Food-restricted rats were initially trained to respond by lever pressing under a fixed-ratio (FR1) schedule of reward presentation (45 mg sucrose pellet, Bio-Serv, Flemington, NJ). Side biases were avoided by presenting each lever an equal number of times in a pseudorandom order. Following training, the 3-phase task was conducted, consisting of position discrimination, position reversal, and rule shifting. During position discrimination, one lever (left or right) was designated as the 'correct' choice. Both levers were presented but only responses on the 'correct' lever were rewarded while responses on the other had no programmed consequences. An inter-trial interval of 20 s followed each response, during which time the levers were retracted. Rats underwent position discrimination until they attained the criterion of 10 consecutive correct trials with a maximum of 150 trials per day. One day following completion of the discrimination phase, the rats performed a reversal learning task in which the opposite lever of the 'correct' choice from the discrimination phase was now rewarded. Twenty reminder trials of the previous rule were conducted prior to the reversal trials. As with position discrimination, rats underwent reversal learning until they attained 10 consecutive correct trials. After successful completion of the reversal task, the strategy shift task was initiated on the following day. In this phase both levers were presented in each trial. In addition, an audible tone was presented above one of the two levers. The 'correct' lever, which resulted in reward presentation, was that which was associated with the tone, regardless of position (left or right) within the chamber. Tone, rather than a cue light, was used in this phase to account for any inherent visual impairment due to cataract development in Tg rats. Rats conducted the strategy shift phase until they attained the criterion of 10 consecutive correct trials, with a maximum of 150 trials on a single day. If animals failed to reach criterion by day 10 of the shift to cue phase, the task was terminated. Cognitive performance was determined by measuring the number of trials needed to reach criterion during each phase of the task, as well as the rate at which they reached criterion.

Neuronal cultures {#s4-4}
-----------------

Primary cortical neurons were obtained from E17 embryos from Holtzmann rats and cultured in Neurobasal medium as previously reported ([@bib7]; [@bib45]; [@bib60]). To further reduce the growth of non-neuronal cells, cytosine arabinoside (1 μM) was added to the cultures. This results in a virtually glia-free culture (\>95% neurons) as assessed by expression of neuronal and non-neuronal markers. Briefly, neurons were plated at a density of 1 × 10^6^ on 60 mm dishes or 35,000 on 15 mm coverslips in Neurobasal medium containing B27 (2%) and horse serum (2%). Medium was replaced after 3 hr of plating with serum-free Neurobasal medium supplemented with B27, Glutamax (0.5 mM), and glutamic acid (25 μM). On the fourth and eighth day in vitro (DIV), the culture medium was replaced again with Neurobasal medium supplemented with B27 and Glutamax. On the fourteenth day of culture, half of the media were changed with Neurobasal medium supplemented with B27 and Glutamax. All experiments were conducted at DIV 21.

Infection of cortical neurons {#s4-5}
-----------------------------

Cortical neurons (DIV 18) were infected with either scramble shRNA or Rac1 shRNA (5'-CGAGGACTCAAGACAGTGTTTGATGAAGC-3'; OriGene Technologies) lentiviral particles. Lentivirus was produced in HEK293T cells (cultured in DMEM and 10% fetal bovine serum) by transfecting cells with either the control or Rac1 shRNA plasmid vector (pGFP-C-shLenti), pCMVR8.74 (Addgene \#22036), and pMD2.G (Addgene \#12259) via calcium phosphate. Supernatants were collected on day 2 and 3 post-transfection and lentiviral particles were isolated via ultracentrifugation (2 hr at 50,000 g, 16°C) and resuspended in 1X PBS. Purified virus was added directly to cortical neurons and resulted in 30--40% infection efficiency. Levels of Rac1 protein were assessed via Western blot (as described below) after 3 days of infection.

Western blot {#s4-6}
------------

For whole-cell lysates, cell lysates were prepared after drug treatment as previously described [@bib60]. Primary neurons were washed in ice-cold PBS, collected in lysis buffer (150 mM NaCl, 50 mM Tris, 0.5% Na deoxycholate, 0.1% SDS, 10 mM Na~4~P~2~O~7~, 5 mM EDTA, 1% Triton-X 100, 1 mM DTT, and protease/phosphatase inhibitors), and then incubated for 30 min on a rotor at 4°C. After 30 min, lysates were spun at 20,800 *x g* for 10 min and the protein concentration of the supernatants was determined using bicinchoninic acid (BCA) assay following the instructions of the manufacturer (Pierce). Equal amounts of protein (30--40 μg/lane) were loaded for SDS-PAGE followed by immunoblotting.

For tissue homogenates, brain cortices were rapidly removed, and a 5 mm portion of the frontal cortex was separated using a brain matrix. Tissue was dissociated by pipetting and incubated for 1 hr at 4°C with frequent vortexing. Lysates were then centrifuged at 20,800 *x g* for 10 min at 4°C and protein concentration was assessed via BCA assay. Equal amounts of protein (30--40 μg/lane) were used for SDS-PAGE followed by immunoblotting.

The following antibodies were used: anti-pPAK1 (Thr423, Cell Signaling Technology, 1:1000, RRID:[AB_330220](https://scicrunch.org/resolver/AB_330220)), anti-PAK1 (Cell Signaling Technology, 1:1000, RRID:[AB_330222](https://scicrunch.org/resolver/AB_330222)), anti-pLIMK1 (Thr507/508, EMD Millipore, 1:1000, RRID:[AB_568901](https://scicrunch.org/resolver/AB_568901)), anti-LIMK1 (Cell Signaling Technology, 1:1000, RRID:[AB_2281332](https://scicrunch.org/resolver/AB_2281332)), anti-pCofilin (Ser3, Cell Signaling Technology, 1:1000, RRID:[AB_330238](https://scicrunch.org/resolver/AB_330238)), anti-cofilin (Cell Signaling Technology, 1:1000, RRID:[AB_10622000](https://scicrunch.org/resolver/AB_10622000)), anti-pSSH1L (Ser978, ECM Biosciences, 1:500, RRID:[AB_10553849](https://scicrunch.org/resolver/AB_10553849)), anti-SSH1 (Cell Signaling Technology, 1:1000, RRID:[AB_2798263](https://scicrunch.org/resolver/AB_2798263)), anti-Rac1 (Cell Biolabs, 1:6000), and anti-β-actin (Sigma-Aldrich, 1:6000, RRID:[AB_476693](https://scicrunch.org/resolver/AB_476693)).

Rac1 activation assay {#s4-7}
---------------------

The Rac1 activation assay was performed using Cell Biolabs Rac1 Activity Assay Kit (\#STA-401--1). Briefly, cells or tissue were lysed as described above and the active form of Rac1 (GTP-Rac1) was selectively pulled down from the lysate with p21-binding domain (PBD) of PAK agarose beads. Subsequently, the precipitated GTP-Rac1 was detected by Western blot analysis as described above. Each assay also consisted of lysates that were loaded with GTPγS or GDP as positive and negative controls respectively. A separate Western blot was run to evaluate total levels of Rac1 in each lysate.

F/G-actin ratio {#s4-8}
---------------

F/G-actin ratio was assessed as previously described [@bib46]. Briefly, cells were lysed in cold lysis buffer \[10 mM K~2~PO~4~, 100 mM NaF, 50 mM KCl, 2 mM MgCl~2~, 1 mM EGTA, 0.2 mM DTT, 0.5% Triton-X 100, 1 mM sucrose (pH 7.0)\] and centrifuged at 15,000 *x g* for 30 min. Separation of F-actin and G-actin was achieved in that F-actin is insoluble (pellet) in this buffer, whereas G-actin is soluble (supernatant). The G-actin supernatant was transferred to a fresh tube and the F-actin pellet was resuspended in lysis buffer plus an equal volume of a second buffer \[1.5 mM guanidine hydrochloride, 1 mM sodium acetate, 1 mM CaCl~2~, 1 mM ATP, 20 mM tris-HCl (pH 7.5)\] and then incubated on ice for one hour with gentle mixing every 15 min to convert F-actin into soluble G-actin. Samples were centrifuged at 15,000 *x g* for 30 min and the supernatant (containing F-actin which was converted to G-actin) was transferred to a fresh tube. F-actin and G-actin samples were loaded with equal volumes and analyzed via Western blot. Latrunculin A (5 μM, 2 hr), a potent actin polymerization inhibitor, and jaspakinolide (5 μM, 2 hr), an inducer of actin polymerization, were used as internal controls for the assay.

Immunocytochemistry {#s4-9}
-------------------

Immunocytochemistry was performed as previously described [@bib45]. Cells were washed in PBS, fixed in 2% paraformaldehyde (PFA) for 10 min at room temperature and 4% PFA at 4°C for 20 min, and permeabilized with 0.1% Triton-X 100 for five minutes. Blocking was performed with 5% normal goat serum for 30 min. The following primary and secondary antibodies were used: anti-MAP2 (Millipore, 1:1000, RRID:[AB_91939](https://scicrunch.org/resolver/AB_91939)) and goat anti-rabbit Alexa Fluor 568 (Invitrogen, 1:250, RRID:[AB_143157](https://scicrunch.org/resolver/AB_143157)). Cells were counterstained with both Hoechst (Invitrogen, 1:10,000) and phalloidin Alexa Fluor 488 (Invitrogen, 1:400). After staining, coverslips were rinsed in H~2~O and mounted using ProLong Gold Antifade mounting media (Invitrogen).

DiOlistic labeling of brain slices {#s4-10}
----------------------------------

Rats were sacrificed following the end of behavioral studies. Brains were rapidly removed, rinsed in H~2~O, fixed in 4% PFA for 1 hr, and washed 3 times in 1X PBS. After fixation, serial coronal slices were sectioned via vibratome at a thickness of 150 μm and placed in tissue culture plates until further processing. DiOlistic labeling was performed according to published techniques ([@bib59]). 300 mg of tungsten beads (Bio-Rad, Hercules, CA) were suspended in 99.5% pure methylene chloride (Fisher Scientific) and sonicated in a water bath for 1 hr. Crystalized DiI (13.5 mg; Invitrogen) was dissolved in methylene chloride and protected from light. Following sonication, 100 μL of the tungsten bead solution was placed on a glass slide and 100 μL of DiI solution titrated on top, which was slowly mixed using a pipette tip and allowed to dry. A razor blade was used to collect the dry bead/dye mixture onto weigh paper, placed into a 15 mL conical tube with 3 mL ddH~2~O, and sonicated in a water bath for 20 min. The bead/dye mixture was drawn into Tezfel tubing coated with polyvinylpyrrolidone (Sigma-Aldrich, St. Louis, MO) and dried using nitrogen gas for 1 hr. Once dry, tubing was cut into 13 mm cartridges and loaded into the Helios Gen Gun (Bio-Rad). Helium gas flow was adjusted to 120 PSI and bullets were delivered to slices through 3 μm pore filter paper. Slices were quickly washed 3 times with 1X PBS and stored overnight at 4°C to allow diffusion of the dye. The following day, slices were mounted using ProLong Gold Antifade (Invitrogen), coverslipped, and stored at 4°C until imaging.

Dendritic spine analysis {#s4-11}
------------------------

For in vitro experiments, neurons were cultured for 21 days, then fixed and stained for MAP2 (Alexa 568) and counterstained with phalloidin (Alexa 488) or infected with GFP-tagged lentiviral particles, as described above. Images were acquired with the Olympus FLUOVIEW FV3000 confocal microscope equipped with a 100x silicone oil-immersion objective at 2x electronic zoom and taken at 0.5 μm Z steps. Neurolucida 360 software (MBF Bioscience) was utilized to automatically quantify dendritic spines, as well as classify them into their respective morphologies based on established parameters ([@bib50]). For each experiment, four dendrites, at least 100--150 μm in length, from each coverslip were analyzed and a total of three coverslips were imaged for each condition. Each coverslip was averaged as a single data point and the experiment was repeated across three separate neuronal dissections.

For in vivo studies, dendrites in layer II/III pyramidal neurons from the prelimbic (PrL) region of the mPFC were imaged using the Olympus FLUOVIEW FV3000 using a 100x silicone oil-immersion objective at 2x electronic zoom and taken at 0.15 μm Z-steps. Neurolucida 360 software was used as mentioned above. Eight dendrites, at least 100--150 μm in length, were analyzed from eight separate neurons and averaged together as a single data point per animal.

Tyramide stain and amplification {#s4-12}
--------------------------------

The hemisphere contralateral to the one used for DiOlistic staining was fixed in 4% PFA for 24 hr, moved to 70% ethanol, and then paraffin embedded and sectioned at 5 μm for immunohistochemical analysis. Tissue was sequential dual-stained with pPAK1 (Thr423, Invitrogen, 1:25, RRID:[AB_2554427](https://scicrunch.org/resolver/AB_2554427)) and the neuronal marker NeuN (Cell Signaling, 1:400, RRID:[AB_2651140](https://scicrunch.org/resolver/AB_2651140)). After rehydration, antigen retrieval was performed in a citrate buffer (Life Technologies) at 95°C for 20 min followed by quenching of endogenous peroxidase activity with hydrogen peroxide and methanol for 30 min at room temperature. Tissue was blocked with 10% normal goat serum before incubation with primary antibody overnight at 4°C in a humidity chamber. Secondary antibody (goat anti-rabbit poly-HRP) incubation was performed for 1 hr at room temperature, then amplified with Alexa Fluor conjugated tyramide (Invitrogen, 488 for pPAK1, 555 for NeuN). Tissue was counterstained with Hoescht (Invitrogen, 1:10,000, 5 min), washed in H~2~O, and then mounted with ProLong Gold Antifade mounting media.

Multispectral imaging {#s4-13}
---------------------

Fluorescence microscopy coupled with multispectral image analysis was performed to identify NeuN+ neurons within layer II/III of the PrL region in the mPFC. A spectral library was built to remove autofluorescence and separate out individual fluorescence spectra using Nuance software. The average optical density (OD) per area for pPAK1 was measured within each individual NeuN+ neuron. Two sections per animal were imaged, with three separate pictures taken per section and then averaged into a single data point per animal.

Materials {#s4-14}
---------

Cell culture media was purchased from Invitrogen. Pertussis toxin (PTX) and AMD3100 were from Sigma Aldrich, NSC23766 was from Tocris Bioscience, Latrunculin A and Jaspakinolide were from Santa Cruz Biotechnology, and recombinant CXCL12 from Peprotech. Cannulas were custom-made and purchased from Plastics One. pCMVR8.74 (Addgene plasmid \#22036, RRID:[Addgene_22036](https://scicrunch.org/resolver/Addgene_22036)) and pMD2.G (Addgene plasmid \#12259, RRID:[Addgene_12259](https://scicrunch.org/resolver/Addgene_12259)) were gifts from Didier Trono.

Experimental design and statistical analysis {#s4-15}
--------------------------------------------

The number of animals used for behavioral and in vivo studies was calculated by power analysis using PS: Power and Sample Size Calculation version 3.1.6 (Vanderbilt University). Sample sizes were calculated using an independent measures study design with α = 0.05 and power = 0.8. Male WT or HIV-Tg F344 rats (approximately 4 months old) were randomly assigned to groups for behavioral and in vivo studies. In vivo data collection and analysis was conducted blinded to genotype and treatment. All in vitro experiments were performed with at least N = 3 biological replicates, and each biological replicate used neurons derived from a different litter of E17 rats. Outliers were neither encountered nor removed from any analysis. Data are represented as mean ± SEM for in vitro and in vivo experiments. The number of trials to criterion for each behavioral task was analyzed using a two-tailed Student's t-test or one-way ANOVA followed by Tukey post hoc. Dendritic spine density and morphology were analyzed using a two-tailed Student's t-test or one-way ANOVA followed by Dunnett post hoc if comparing experimental groups to a control group or Tukey post-hoc if comparing all groups against each other. The correlation between spine density and trials to criterion was calculated as Pearson's *r*. The rate for reaching criterion was assessed by linear regression analysis to determine if the slopes of each line were equal. For multispectral imaging, a two-tailed Student's t-test was used. For the remaining in vitro studies, statistical significance was determined by two-tailed Student's t-test or one-way ANOVA followed by Dunnett post hoc. A p\<0.05 was considered statistically significant. P and n are reported in the figure legends; for correlation analysis, r values are also reported in the text. Additional information regarding statistical analyses and raw data are provided in the source data files for each figure. All statistical analysis was performed with GraphPad Prism, version 8.0 (GraphPad Software, RRID:[SCR_015382](https://scicrunch.org/resolver/SCR_015382)).
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Cognitive deficits are a serious complication associated with AIDS even in treated subjects. Festa and colleagues report that activation of CXCL12/CXCR4 signaling in prefrontal cortex of HIV-Tg rat, an animal model of HAND and provide evidence that the pathological deficits in dendritic spine density and maturation can be reversed by infusion of CXCL12 through the Rac1/PAK actin polymerization pathway. The authors report an interesting set of findings identify a new mechanism and open up important new directions of investigation.

**Decision letter after peer review:**

Thank you for submitting your article \"CXCL12-induced rescue of cortical dendritic spines and cognitive flexibility\" for consideration by *eLife* and your patience. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jonathan Cooper as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Norman Haugey (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by Festa and colleagues reports activation of CXCL12/CXCR4 signaling in prefrontal cortex of HIV-Tg rat, an animal model of HAND. Moreover, they provide evidence that the pathological deficits in dendritic spine density and maturation can be reversed by infusion of CXCL12 through the Rac1/PAK actin polymerization pathway.

Specifically, the authors showed that HIV-Tg rat showed 1) impaired attentional set-shifting behavior, which is correlated with the loss of spine density in the mPFC 2) CXCL12 treatment through ICV infusion rescued the deficit in spine density and attentional set-shifting behavior and 3) CXCL12-induced rescue effect was mediated through the CXCR4/Rac1/PAK actin polymerization pathway.

Cognitive deficits are a serious complication associated with AIDS even in treated subjects. The authors report an interesting set of findings that start to identify a new mechanism. However, in vivo validation and evidence of this CXCL12/CXCR4/Rac1/PAK signaling mechanism would significantly strengthen this study and its impact. Moreover, a few key points and questions need to be addressed as outlined below.

Essential revisions:

1\) Is there a deficit in CXCL12/CXCR4/Rac1/PAK signaling in the HIV-Tg model? Most of the studies of signaling pathways were carried out with cultured WT neurons. It would be important to characterize the signaling changes in PFC of the HIV-Tg model.

2\) CXCR4-independent effects of CXCL12 should be considered. Chemokines are known to have multiple targets. For example, CXCL12 can activate receptors such as CXCR7. Please address in Discussion.

Additional comments:

1\) Is the result in Figure 1A sufficiently powered? It appears that the HIV-Tg result is higher than WT.

2\) The results in Figure 5A, 5B, 5C and Figure 6C suggest that the pLIMK1/LIMK1 findings are not consistent.

3\) Thin spine density in Figure 8D (WT) is similar with Figure 9D (HIV-Tg), which is not consistent with Figure 3D.

4\) The method for labelling spines in vivo does not seem to be included in the paper

Representative images of in vivo spine density and morphology for some of the in vivo pathological and behavioral reversals would be useful for completeness.

5\) It is interesting that the most robust effect of CXCL12 appears to be on thin spines with a reciprocal reduction in stubby spines. These findings are entirely consistent with their data on cytoskeletal stabilization, and suggest that CXCL12 promotes the elongation of stubby spines. It is somewhat curious that the behavioral effects do not appear to correlate with the increased presence of mushroom shaped spines, as these presumably would be synaptically connected. It is possible this effect is due to the timing of CXCL12 infusions, behavioral testing and sacrifice date. i.e. it is possible that the increase of mushroom shaped spines occurred earlier during the infusion regimen and subsequently downregulated after the behavioral task was mastered, or it is possible that the presence of mushroom shaped spines does not accurately reflect synaptic connectivity. PSD95 staining or Western would address the curiosity. If the authors do not have sufficient tissue left over (even contralateral side may be sufficient based on their data), a further discussion of this phenomenon would be sufficient.
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Author response

> Essential revisions:
>
> 1\) Is there a deficit in CXCL12/CXCR4/Rac1/PAK signaling in the HIV-Tg model? Most of the studies of signaling pathways were carried out with cultured WT neurons. It would be important to characterize the signaling changes in PFC of the HIV-Tg model.

This issue is addressed in Figure 7, which has been updated to clearly show CXCL12-induced activation of PAK in the PFC of WT and HIV-Tg rats. Additionally, new related studies are included in Figure 7---figure supplement 1. The short answer to the reviewer's question is *No* -- i.e. the ability of the chemokine to activate Rac1/PAK signaling remains intact in the HIV-Tg model.

More specifically, though the level of PAK phosphorylation in PFC neurons of control (i.e. vehicle treated) HIV-Tg rats is lower than in the corresponding WT group, CXCL12 effectively induces PAK phosphorylation in the HIV-Tg brain and this stimulation is as pronounced as that observed in WT rats (Figure 7A). When compared to the basal value in their respective controls, the magnitude of pPAK increase is comparable in the two groups (average signal per area D = 37 in Tg rats and 36 in WT rats; Figure 7A bottom graph). As predicted from the robust CXCL12-induced PAK stimulation in both genotypes, we did not find significative difference in the expression of total Rac1 protein in HIV-Tg PFC tissue versus WT (Figure 7---figure supplement 1).However, in line with the above pPAK results under basal conditions, pulldown studies from PFC of untreated rats show reduced levels of active Rac1 in HIV-Tg compared to untreated WT (Figure 7---figure supplement 1) -- suggesting a reduced basal tone of PAK activation in the HIV-Tg model.

Overall, these studies indicate that the CXCL12/CXCR4/Rac1/PAK pathway is fully functional in the HIV-Tg model -- a conclusion further supported by the finding that the ability of CXCL12 to rescue spine deficits in the HIV-Tg model is completely blocked by the Rac1 inhibitor (Figure 9).

> 2\) CXCR4-independent effects of CXCL12 should be considered. Chemokines are known to have multiple targets. For example, CXCL12 can activate receptors such as CXCR7. Please address in Discussion.

We recognize the contribution of CXCR7 to other CXCL12 functions and, as suggested by the reviewer, we have discussed this point in the revised manuscript. However, evidence pointing to a main role of CXCR4 in these effects comes not only from the signaling studies presented in this manuscript (Figure 4), but also from previous findings concerning the role of CXCL12/CXCR4 in excitatory neurotransmission and its regulation by endogenous and exogenous factors (e.g. Sengupta et al., 2009, Nicolai et al., 2010, Pitcher et al., 2014, Nash et al., 2019). Additionally, CXCR7 expression on the plasma membrane of differentiated neurons is thought to be modest in the adult brain (e.g. Shimizu et al., 2011). This receptor is certainly critical during development, as it regulates migration of neural precursors and CXCR4 signaling. However, it does not signal via the canonical G-protein coupling and appears less relevant in this specific context.

> Additional comments:
>
> 1\) Is the result in Figure 1A sufficiently powered? It appears that the HIV-Tg result is higher than WT.

The reviewer is correct -- we performed additional statistical analysis and revised both Figure 1 and the text. Thank you for pointing this out.

> 2\) The results in Figure 5A, 5B, 5C and Figure 6C suggest that the pLIMK1/LIMK1 findings are not consistent.

The experiments reported in these figures were performed in primary neurons and conducted over a period of several months. Thus, some variability in the time course is to be expected as these studies come from 12 different cultures (n=3 for each individual set of experiment) and multiple rat embryos. That said, CXCL12 consistently stimulated PAK activation, with peaks at 5-15 minutes. LIMK1 phosphorylation is downstream PAK and was also consistently activated during the first 30-60 minutes, as one would expect. While there is biological variability due to the use of primary tissue over an extended period of time and the complexity of the biochemical process in question, we do typically see subsequent stimulation of the downstream targets within the PAK/LIMK1/cofilin pathway.

> 3\) Thin spine density in Figure 8D (WT) is similar with Figure 9D (HIV-Tg), which is not consistent with Figure 3D.

In addition to intrinsic biological variability, this may be explained by minor differences related to the source of animals, which changed toward the end of this project. All the experiments utilized the transgenic line generated by Bryant's group at the University of Maryland in 2001 (Reid et al., 2001). However, until recently breeding of the HIV-Tg was licensed to a commercial vendor, i.e. Envigo. In the summer of 2017 Envigo's license was not renewed and they returned the colony to the University of Maryland. At that point, we started purchasing the animals from the University of Maryland directly. Hence, while the experiments in Figures 1, 2, 3, 6, 7, 8 were entirely performed with rats from Envigo, for Figure 9 we used a first set of animals (n=12) from Envigo but the rest (n=24) were provided by the University of Maryland animal facility. Importantly, for both cohort of animals we run the four different groups (Vehicle, CXCL12, NSC, NSC+CXCL12) at the same time. Despite the modest change in the number of thin spines compared to the past (possibly due to slight difference in animal age, housing or environment), the effect of CXCL12 and NSC were highly reproducible within the different cohorts -- which further increased our confidence in the results. Indeed, independently of the thin spine density under basal conditions, CXCL12's effect was clear, and it was consistently inhibited by NSC. Furthermore, the changes in thin spine density nicely correlated with cognitive performance as in the previous studies.We have clarified the issue about the animal source in the revised manuscript.

> 4\) The method for labelling spines in vivo does not seem to be included in the paper
>
> Representative images of in vivo spine density and morphology for some of the in vivo pathological and behavioral reversals would be useful for completeness.

The method is included in the section titled "*Diolistic labeling of brain slices*". As requested, we have added representative images in Figures 2A, 3C and Figure 3---figure supplement 4.

> 5\) It is interesting that the most robust effect of CXCL12 appears to be on thin spines with a reciprocal reduction in stubby spines. These findings are entirely consistent with their data on cytoskeletal stabilization, and suggest that CXCL12 promotes the elongation of stubby spines. It is somewhat curious that the behavioral effects do not appear to correlate with the increased presence of mushroom shaped spines, as these presumably would be synaptically connected. It is possible this effect is due to the timing of CXCL12 infusions, behavioral testing and sacrifice date. i.e. it is possible that the increase of mushroom shaped spines occurred earlier during the infusion regimen and subsequently downregulated after the behavioral task was mastered, or it is possible that the presence of mushroom shaped spines does not accurately reflect synaptic connectivity. PSD95 staining or Western would address the curiosity. If the authors do not have sufficient tissue left over (even contralateral side may be sufficient based on their data), a further discussion of this phenomenon would be sufficient.

We thank the reviewer for the comment and agree on the complexity of the issue. Live imaging studies aiming at further exploring the relationship between the reciprocal changes in thin and stubby spines will help address this question. The idea that CXCL12 promotes elongation of stubby spines is attractive, but it is also possible that CXCL12 stabilizes thin spines by reducing their turnover rate. Spine changes may also result from E/I circuit adaptations. We too were intrigued by potential changes in PSD95 and have been investigating this issue recently. So far, we have not observed modifications in overall PSD95 expression in cultured neurons exposed to CXCL12, but we are currently investigating possible changes at the synaptic level specifically (both in cultured neurons and brain tissue slices). In regard to mushroom spines, they were not significantly affected by CXCL12. This is not that surprising as mushroom spines are the most mature and stable type of spines, typically implicated in long term memory. Thin spines on the other hand are thought to be critical for cognitive flexibility. We modified the Discussion to cover these valid points.

[^1]: Department of Basic and Translational Sciences, University of Pennsylvania School of Dental Medicine, Philadelphia, United States.
